Literature DB >> 3263232

Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide.

R Wilson1, J H McKillop, C Pearson, A K Burnett, I Gunn, A M McNicol, J A Thomson.   

Abstract

The aim of the study was to examine tri-iodothyronine, thyroxine, thyroid antibody and thyrotropin receptor antibody levels in thyroid and peripheral venous blood at the time of surgery in patients with Graves' disease. T cell subset patterns in peripheral and thyroidal venous blood were compared to the distribution of T cell subset patterns within the thyroid gland itself. The results showed that at the time of surgery there were no significant differences in any of the parameters measured between thyroidal and peripheral venous samples. T cell subset patterns within the thyroid gland were subjectively similar to those in the venous samples.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263232      PMCID: PMC1541615     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  12 in total

1.  Rapid simultaneous radioimmunoassay for the measurement of triiodothyronine and thyroxine in unextracted human serum.

Authors:  J G Ljunggren; B Persson; M Tryselius
Journal:  Acta Endocrinol (Copenh)       Date:  1976-03

2.  Dysfunction of suppressor T cells in thyroid glands from patients with Graves' disease.

Authors:  Y Ueki; K Eguchi; T Fukuda; T Otsubo; Y Kawabe; C Shimomura; M Matsunaga; H Tezuka; N Ishikawa; K Ito
Journal:  J Clin Endocrinol Metab       Date:  1987-11       Impact factor: 5.958

3.  The role of thyroid stimulating immunoglobulins of Graves's disease in neonatal thyrotoxicosis.

Authors:  D S Munro; S M Dirmikis; H Humphries; T Smith; G D Broadhead
Journal:  Br J Obstet Gynaecol       Date:  1978-11

4.  Evidence that thyroid-stimulating antibody is produced in the thyroid gland.

Authors:  P Kendall-Taylor; A J Knox; N R Steel; S Atkinson
Journal:  Lancet       Date:  1984-03-24       Impact factor: 79.321

5.  Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.

Authors:  R Wilson; J H McKillop; D W Pearson; G F Cuthbert; J A Thomson
Journal:  J Nucl Med       Date:  1985-09       Impact factor: 10.057

6.  Direct and quantitative measurement by immunoprecipitation assay of anti-thyrotrophin receptor antibodies in sera of patients with Graves' disease.

Authors:  T W de Bruin; D van der Heide; A Querido; M C Krol
Journal:  Clin Endocrinol (Oxf)       Date:  1984-02       Impact factor: 3.478

7.  Relation of thyroid-stimulating immunoglobulins to thyroid function and effects of surgery, radioiodine, and antithyroid drugs.

Authors:  E D Mukhtar; B R Smith; G A Pyle; R Hall; P Vice
Journal:  Lancet       Date:  1975-03-29       Impact factor: 79.321

8.  Evidence for thyroidal secretion of 3,3',5'-triiodothyronine in man and its control by TSH.

Authors:  M J Hooper; J G Ratcliffe; W A Ratcliffe; J Marshall; R E Young; G Ngaei; D H Clark
Journal:  Clin Endocrinol (Oxf)       Date:  1978-03       Impact factor: 3.478

9.  Use of plaque assays to study thyroglobulin autoantibody synthesis by human peripheral blood lymphocytes.

Authors:  S M McLachlan; A G Bird; A P Weetman; R Smith; R Hall
Journal:  Scand J Immunol       Date:  1981-09       Impact factor: 3.487

10.  Thyroid glands in patients with Graves' disease are sources of thyrotropin-binding inhibitory (TBI) activity.

Authors:  M C Arqueros; H Niepomniszcze; J Moreno
Journal:  Acta Endocrinol (Copenh)       Date:  1986-07
View more
  1 in total

1.  The presence of higher levels of thyroglobulin, but not thyroid autoantibodies, in the thyroid vein in Graves' disease.

Authors:  F F Chou; P W Wang; S M Sheen-Chen
Journal:  J Endocrinol Invest       Date:  1994-01       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.